ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024
Organs in plain sight-parotid gland doses in short-course palliative whole-brain radiotherapy.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePalliative whole-brain radiotherapy (WBRT) is a useful treatment modality for patients diagnosed with brain metastasis. Our study aimed to document parotid doses using a short course of 20 Gy in five fractions (SC-WBRT) and compare them with the known xerostomia parameters. METHODS AND MATERIALS: We retrieved dosimetric parameters for 59 patients who received SC-WBRT. The contouring of parotids was done retrospectively. The data was stratified depending on the lower edge of the planning target volume (PTV) border, up to either the first cervical vertebra (C1) or the second cervical vertebra (C2). The biologically effective dose (BED) of the parotid dose constraints from the literature was calculated and corrected to obtain the dose for a five-fraction treatment. These were used as a reference for assessing the parotid doses of our cohort.
resultsWith SC-WBRT, the mean doses of either gland (11.46 Gy) and of total parotids (11.48 Gy) were statistically significantly less than the BED corrected constraints of 12.82 Gy (p < 0.01) and 15.31 Gy (p < 0.01). Patients with PTV to C1, compared to those with a PTV to C2, had significantly lower mean doses of either gland (9.44 Gy vs 12.76 Gy, p < 0.01) and total parotid dose (9.44 Gy vs 12.78 Gy, p < 0.01). Patients with PTV to C1 had doses significantly lower than all the reference dose parameters.
conclusionRoutine delineation and documentation of parotid dosimetry would enable parotid sparing, irrespective of the dose regimen used. SC-WBRT provides better parotid sparing dosimetrically which may reduce the related toxicities even in palliative settings. Limiting the lower border of the PTV to C1 will further decrease the parotid doses.
Indexed as
Identifiers
39666080What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.